
Demant (CPSE:DEMANT) is back in focus after the Oticon Reveal hearing aid launch drew strong market acceptance, prompting management to lift growth and earnings guidance supported by firm US demand.
Recent trading has been strong, with Demant’s share price delivering a 21.06% 1 month share price return and 27.74% over 3 months. The 58.97% 1 year total shareholder return suggests momentum has been building around the Oticon Reveal story rather than fading.
Compare Demant’s momentum with other healthcare stocks that screen well on quality and valuation using our curated list of 184 high quality undervalued stocks.
After a 12 month total return of 58.97% and a share price above the current analyst target, Demant now splits opinion. Is Oticon Reveal still creating upside, or has most of the rerating already happened?
Against a last close of DKK356.40, the most followed Demant valuation narrative points to a fair value of DKK309.55 using a 6.28% discount rate, which frames the current Oticon Reveal enthusiasm as richer than that central estimate.
Operational discipline with tightened cost control during periods of weak market growth, alongside plans for efficiency gains and scale benefits from integration, positions Demant to expand margins as volumes recover, enabling a more leveraged return to profit growth once secular demand trends reassert themselves.
See why 6 investors see Demant as 15% overvalued.
Result: Fair Value of DKK309.55 (OVERVALUED)
Still, if hearing aid demand remains subdued for longer or competition forces Demant to lean harder on lower priced markets, the 15% overvaluation narrative could gain traction.
Find out about the key risks to this Demant narrative.
The analyst fair value narrative presents Demant as 15% overvalued at DKK356.40. The SWS DCF model tells a different story. On that framework, Demant screens as undervalued, with the share price trading at a 37.2% discount to an estimated future cash flow value of DKK567.28. That gap raises a simple question for investors: Which set of assumptions feels more realistic?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Demant for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 184 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Mixed signals on Demant so far. If you want to move fast and build your own conviction, start by weighing both the upside drivers and the caution flags in the 2 key rewards and 1 important warning sign.
If Demant sharpened your focus, do not stop here. Broaden your watchlist with other opportunities that match your style, before the market prices them in.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com